Anti-GPE antibodies, their uses, and analytical methods for GPE

Abstract

GPE antibodies recognize GPE with high specificity. When used in a radioimmunoassay, they reliably measure the concentration of GPE. They may be used to extend the half-life of GPE both in vivo and in vitro, and in methods of purifying the GPE receptor. Two methods of rpHPLC accurately revolve GPE on the basis of its hydrophobicity.

We claim:  
     
         1 . An anti-GPE antibody.  
     
     
         2 . The antibody of  claim 1  having the ability to specifically bind to GPE at a final titer of 1:600 using  125 I-YGPE tracer.  
     
     
         3 . The antibody of  claim 1  having the ability to bind to GPE in normal tissue.  
     
     
         4 . The antibody of  claim 1  having the ability to bind to GPE in diseased or injured tissue of the central or peripheral nervous system.  
     
     
         5 . The antibody of  claim 1  that is the CK5 antibody.  
     
     
         6 . An antibody to Bolton and Hunter derivatized GPE.  
     
     
         7 . An antibody to Bolton and Hunter derivatized GPE having the ability to specifically bind to Bolton and Hunter derivatized GPE at a final titer of 1:18,000 using Bolton and Hunter derivatized  125 I-YGPE tracer.  
     
     
         8 . Anti-GPE antiserum.  
     
     
         9 . A reverse-phase HPLC method for the detection of GPE in a sample of body fluid or tissue, comprising: 
 (a) derivatizing the sample with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate,    (b) eluting the sample in a reverse phase HPLC system, and    (c) detecting the GPE by excitation at 250 nm and detection at 395 nm.    
     
     
         10 . An rpHPLC assay kit for the practice of the method of  claim 9  comprising a GPE standard, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate and derivatizing buffer, a column, and column running buffer.  
     
     
         11 . A reverse-phase HPLC method for the detection of radioactive GPE in a sample of body fluid or tissue, comprising: 
 (a) eluting the sample in a reverse phase HPLC system, and    (b) detecting the GPE by detection of the emitted radioactivity.    
     
     
         12 . An rpHPLC assay kit for the practice of the method of  claim 11 , comprising a radioactive GPE standard, a column, and column running buffer.  
     
     
         13 . A radioimmunoassay kit for the detection or quantitation of GPE, comprising the antibody of  claim 1 , a GPE standard, an assay buffer, a purified hormone for iodination and a second antibody or a precipitated antibody.  
     
     
         14 . An radioimmunoassay kit for the detection or quantitation of GPE, comprising the antibody of  claim 1 , a GPE standard, an assay buffer, tritiated GPE, and a second antibody or precipitating antibody.  
     
     
         15 . A radioimmunoassay kit for the detection or quantitation of GPE comprising the antibody of  claim 1 , a GPE standard, Bolton and Hunter reagent, a derivatizing buffer, an assay buffer, Bolton and Hunter derivatized GPE for iodination, and a second antibody or precipitating antibody.  
     
     
         16 . A method of isolating or purifying the GPE receptor from a sample, comprising: 
 (a) treating the sample with GPE to form a GPE-(GPE receptor) complex,    (b) treating the sample with the antibody of  claim 1  conjugated to a photoactivatable binding group,    (c) photoactivating the binding group to form an antibody-GPE-(GPE receptor) complex,    (d) isolating the complex from the sample, and    (e) releasing the GPE receptor from the complex and isolating or purifying it.    
     
     
         17 . A method of extending the half-life of GPE, or of modulating the free concentration of GPE, comprising co-administering GPE and the antibody of  claim 1 .  
     
     
         18 . The method of  claim 17  comprising co-administering GPE and the antibody of  claim 1  in vivo.  
     
     
         19 . The method of  claim 17  comprising co-administering GPE and the antibody of  claim 1  to a mammal.  
     
     
         20 . A method of extending the half-life of GPE, or of modulating the free concentration of GPE, in a mammal, comprising administering the antibody of  claim 1  to the mammal.